[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PL335695A1 - Method of integrating genes into a specific place of mammal cell genome by honologous recombination and vectors serving that purpose - Google Patents

Method of integrating genes into a specific place of mammal cell genome by honologous recombination and vectors serving that purpose

Info

Publication number
PL335695A1
PL335695A1 PL98335695A PL33569598A PL335695A1 PL 335695 A1 PL335695 A1 PL 335695A1 PL 98335695 A PL98335695 A PL 98335695A PL 33569598 A PL33569598 A PL 33569598A PL 335695 A1 PL335695 A1 PL 335695A1
Authority
PL
Poland
Prior art keywords
recombination
honologous
cell genome
specific place
mammal cell
Prior art date
Application number
PL98335695A
Other versions
PL191251B1 (en
Inventor
Mitchell E Reff
Richard Spence Barnett
Karen Retta Mclachlan
Original Assignee
Idec Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26697516&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL335695(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/819,866 external-priority patent/US5830698A/en
Application filed by Idec Pharma Corp filed Critical Idec Pharma Corp
Publication of PL335695A1 publication Critical patent/PL335695A1/en
Publication of PL191251B1 publication Critical patent/PL191251B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

A method for achieving site specific integration of a desired DNA at a target site in a mammalian cell via homologous recombination is described. This method provides for the reproducible selection of cell lines wherein a desired DNA is integrated at a predetermined transcriptionally active site previously marked with a marker plasmid. The method is particularly suitable for the production of mammalian cell lines which secrete mammalian proteins at high levels, in particular immunoglobulins. Novel vectors and vector combinations for use in the subject cloning method are also provided.
PL335695A 1997-03-14 1998-03-09 Method for integrating genes at specific sites of mammalian cell genome via honologous recombination and vectors for accomplishing the same PL191251B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/819,866 US5830698A (en) 1997-03-14 1997-03-14 Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same
US09/023,715 US5998144A (en) 1997-03-14 1998-02-13 Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same
PCT/US1998/003935 WO1998041645A1 (en) 1997-03-14 1998-03-09 Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same

Publications (2)

Publication Number Publication Date
PL335695A1 true PL335695A1 (en) 2000-05-08
PL191251B1 PL191251B1 (en) 2006-04-28

Family

ID=26697516

Family Applications (1)

Application Number Title Priority Date Filing Date
PL335695A PL191251B1 (en) 1997-03-14 1998-03-09 Method for integrating genes at specific sites of mammalian cell genome via honologous recombination and vectors for accomplishing the same

Country Status (21)

Country Link
US (3) US6413777B1 (en)
EP (1) EP0981637B1 (en)
JP (1) JP4128227B2 (en)
CN (1) CN1175111C (en)
AT (1) ATE296356T1 (en)
AU (1) AU737155B2 (en)
BR (1) BR9808584A (en)
CA (1) CA2283740C (en)
CZ (1) CZ293355B6 (en)
DE (1) DE69830312T2 (en)
ES (1) ES2242997T3 (en)
ID (1) ID24565A (en)
IL (1) IL131746A0 (en)
IN (1) IN189732B (en)
NO (1) NO994397L (en)
PL (1) PL191251B1 (en)
PT (1) PT981637E (en)
RO (1) RO120148B1 (en)
RU (1) RU2004107694A (en)
TW (1) TWI232239B (en)
WO (1) WO1998041645A1 (en)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830698A (en) * 1997-03-14 1998-11-03 Idec Pharmaceuticals Corporation Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same
ID24565A (en) * 1997-03-14 2000-07-27 Idec Pharma Corp METHODS FOR GEN INTEGRATION IN SPECIFIC PLACES IN MAMALIA CELLS THROUGH HOMOLOGIC AND VECTOR RECOMBINATIONS FOR THE SAME ACHIEVEMENT
IL136574A0 (en) 1997-12-08 2001-06-14 California Inst Of Techn A method for forming a polynucleotide of desired properties
WO2000039304A2 (en) 1998-12-31 2000-07-06 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
GB9912965D0 (en) * 1999-06-03 1999-08-04 Oxford Biomedica Ltd In vivo selection method
CA2389633A1 (en) 1999-11-01 2001-05-10 Chiron Corporation Expression vectors, transfection systems, and method of use thereof
CN1322138C (en) * 2000-06-23 2007-06-20 诺维信公司 Method for stable chromosomal multi-copy integration of genes
AU2002320314A1 (en) 2001-07-05 2003-01-21 Chiron, Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
CA2467363A1 (en) 2001-11-16 2003-06-12 Idec Pharmaceuticals Corporation Polycistronic expression of antibodies
US7164056B2 (en) * 2002-05-03 2007-01-16 Pioneer Hi-Bred International, Inc. Gene targeting using replicating DNA molecules
CN105884893A (en) 2002-07-18 2016-08-24 莫鲁斯有限公司 Recombinant Production Of Mixtures Of Antibodies
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
US20040170614A1 (en) * 2002-10-30 2004-09-02 Gail Bishop Somatic cell gene targeting vectors and methods of use thereof
CA2512647C (en) * 2003-01-07 2013-10-08 Symphogen A/S Method for manufacturing recombinant polyclonal proteins
EP1587932B1 (en) * 2003-01-31 2009-03-25 Icon Genetics GmbH Plant transformation with in vivo assembly of a trait
DE10303937A1 (en) * 2003-01-31 2004-08-12 Icon Genetics Ag Plant transformation with assembly of a desired sequence in vivo
ATE479754T1 (en) 2003-03-19 2010-09-15 Biogen Idec Inc NOGO RECEPTOR BINDING PROTEIN
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
NZ568403A (en) * 2003-05-09 2009-10-30 Univ Duke CD20-specific antibodies and methods of employing same
ES2408582T3 (en) 2003-05-30 2013-06-21 Merus B.V. Fab library for the preparation of a mixture of antibodies
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
JP5091476B2 (en) * 2003-06-27 2012-12-05 バイオジェン・アイデック・エムエイ・インコーポレイテッド Use of hydrophobic interaction chromatography or hinge region modification to generate homogeneous antibody solutions
ATE532861T1 (en) * 2003-09-04 2011-11-15 Medarex Inc EXPRESSION VECTOR
US8030833B2 (en) * 2003-09-19 2011-10-04 The Board Of Trustees Of The University Of Illinois Electron emission device incorporating free standing monocrystalline nanowires
US7344753B2 (en) * 2003-09-19 2008-03-18 The Board Of Trustees Of The University Of Illinois Nanostructures including a metal
US7935862B2 (en) * 2003-12-02 2011-05-03 Syngenta Participations Ag Targeted integration and stacking of DNA through homologous recombination
NZ548828A (en) 2004-01-20 2009-07-31 Merus B V Mixtures of binding proteins
BRPI0512500A (en) 2004-06-24 2008-03-11 Biogen Idec Inc treatment or conditions involving demyelination
ES2381531T3 (en) 2004-07-20 2012-05-29 Symphogen A/S A method of structural characterization of a recombinant polyclonal protein or a polyclonal cell line
EP1789070B1 (en) 2004-08-03 2012-10-24 Biogen Idec MA Inc. Taj in neuronal function
FR2879204B1 (en) * 2004-12-15 2007-02-16 Lab Francais Du Fractionnement CYTOTOXIC ANTIBODY AGAINST HEMATOPOIETIC B-TYPE HEMATOPOIETIC PROLIFERATIONS
DK1838736T3 (en) 2005-01-05 2013-06-03 Biogen Idec Inc Crypto-binding molecules
CN100381573C (en) * 2005-04-14 2008-04-16 北京天广实生物技术有限公司 System and method of mammalian cell strain for fast constructing target gene high expression
CA2902070A1 (en) 2005-07-08 2007-01-18 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
WO2007035213A2 (en) * 2005-08-09 2007-03-29 Revivicor, Inc. Transgenic ungulates expressing ctla4-ig and uses thereof
WO2007056161A1 (en) 2005-11-04 2007-05-18 Biogen Idec Ma Inc. Methods for promoting neurite outgrowth and survival of dopaminergic neurons
NZ598421A (en) 2005-12-02 2013-11-29 Biogen Idec Inc Treatment of Conditions Involving Demyelination
WO2007064911A1 (en) * 2005-12-02 2007-06-07 Biogen Idec Inc. Anti-mouse cd20 antibodies and uses thereof
PT1981902E (en) 2006-01-27 2015-11-02 Biogen Ma Inc Nogo receptor antagonists
LT2436696T (en) 2007-01-05 2017-08-25 University Of Zurich Anti-beta-amyloid antibody and uses thereof
ES2464815T3 (en) 2007-01-09 2014-06-04 Biogen Idec Ma Inc. SP35 antibodies and their uses
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
WO2008097503A2 (en) 2007-02-02 2008-08-14 Biogen Idec Ma Inc. Use of semaphorin 6a for promoting myelination and oligodendrocyte differentiation
CA2701189C (en) * 2007-10-11 2017-05-16 Biogen Idec Ma Inc. Methods for treating pressure induced optic neuropathy, preventing neuronal degeneration and promoting neuronal cell survival via administration of lingo-1 antagonists and trkb agonists
JP5754046B2 (en) * 2007-11-08 2015-07-22 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． Use of a LINGO-4 antagonist in the treatment of conditions involving demyelination
AU2008335178A1 (en) * 2007-12-10 2009-06-18 Ablexis Llc Methods for sequential replacement of targeted region by homologous recombination
AU2009269099B2 (en) 2008-07-09 2016-03-10 Biogen Ma Inc. Compositions comprising antibodies to LINGO or fragments thereof
KR102362774B1 (en) 2008-09-30 2022-02-15 아블렉시스, 엘엘씨 Non-human mammals for the production of chimeric antibodies
AU2009328505B2 (en) 2008-12-19 2014-11-27 Panima Pharmaceuticals Ag Human anti-alpha-synuclein autoantibodies
CN102341411A (en) 2008-12-31 2012-02-01 比奥根艾迪克Ma公司 Anti-lymphotoxin antibodies
AU2010228990A1 (en) 2009-03-24 2011-10-27 Teva Biopharmaceuticals Usa, Inc. Humanized antibodies against LIGHT and uses thereof
CN102639699A (en) 2009-10-01 2012-08-15 Toto株式会社 DNA construct, and process for production of recombinant CHO cell using same
NZ601171A (en) 2010-03-31 2014-11-28 Ablexis Llc Genetic engineering of non-human animals for the production of chimeric antibodies
SG184903A1 (en) * 2010-04-30 2012-11-29 Temasek Life Sciences Lab Ltd Fragment switch: a reverse genetic approach
DK2591099T3 (en) 2010-07-09 2021-02-15 Bioverativ Therapeutics Inc CHIMARY COAGULATION FACTORS
US8940272B2 (en) 2010-10-11 2015-01-27 University Of Zurich Human anti-tau antibodies
DK2640743T3 (en) 2010-11-16 2017-01-23 Excelimmune Inc PROCEDURES FOR THE PREPARATION OF RECOMBINANT PROTEINS
JP5209693B2 (en) * 2010-12-10 2013-06-12 ロンザ・バイオロジクス・ピーエルシー Methods for expressing recombinant proteins in CHO cells
US9283271B2 (en) 2010-12-17 2016-03-15 Neurimmune Holding Ag Human anti-SOD1 antibodies
PT2723379T (en) 2011-06-23 2018-11-14 Univ Of Zuerich Anti-alpha synuclein binding molecules
WO2013012733A1 (en) 2011-07-15 2013-01-24 Biogen Idec Ma Inc. Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto
US8962315B2 (en) 2011-12-22 2015-02-24 Elwha Llc Compositions and methods including recombinant B lymphocyte cell line including at least one endogenous gene expressing at least one endogenous membrane immunoglobulin reactive to a first antigen and including at least one exogenously incorporated nucleic acid expressing at least one exogenous secreted immunoglobulin reactive to a second antigen
US9175072B2 (en) 2011-12-22 2015-11-03 Elwha Llc Compositions and methods including recombinant B lymphocyte cell line including an exogenously incorporated nucleic acid expressing an exogenous membrane immunoglobulin reactive to a first antigen and including an endogenous gene expressing an endogenous secreted immunoglobulin reactive to a second antigen
US10745468B2 (en) 2011-12-22 2020-08-18 Kota Biotherapeutics, Llc Compositions and methods for modified B cells expressing reassigned biological agents
US10233424B2 (en) 2011-12-22 2019-03-19 Elwha Llc Compositions and methods including cytotoxic B lymphocyte cell line expressing exogenous membrane immunoglobulin different from secreted immunoglobulin
NZ772318A (en) 2012-04-20 2023-06-30 Merus Nv Methods and means for the production of ig-like molecules
WO2013163394A1 (en) 2012-04-25 2013-10-31 Regeneron Pharmaceuticals, Inc. Nuclease-mediated targeting with large targeting vectors
JP6559063B2 (en) 2012-05-07 2019-08-14 サンガモ セラピューティクス， インコーポレイテッド Methods and compositions for nuclease-mediated targeted integration of transgenes
AU2013262934B2 (en) 2012-05-14 2018-02-01 Biogen Ma Inc. LINGO-2 antagonists for treatment of conditions involving motor neurons
AU2013270683A1 (en) 2012-06-08 2014-12-11 Biogen Ma Inc. Chimeric clotting factors
BR112015007780A2 (en) 2012-10-09 2017-11-28 Biogen Idec Inc anti-lingo-1 antibody molecule, its use for treating demyelinating disorders, kit and packaged composition
BR112015014751A8 (en) 2012-12-21 2018-01-16 Biogen Int Neuroscience Gmbh human anti-tau antibodies and tau binding fragment thereof, their use in the preparation of a medicament, as well as polypeptides encoding them.
CA2896824A1 (en) 2012-12-31 2014-07-03 Neurimmune Holding Ag Recombinant human antibodies for therapy and prevention of polyomavirus-related diseases
EP3889173B1 (en) 2013-02-15 2023-07-05 Bioverativ Therapeutics Inc. Optimized factor viii gene
EA037906B1 (en) 2013-03-15 2021-06-04 Биовератив Терапьютикс Инк. Factor ix polypeptide formulations
EP3160478A4 (en) 2014-06-30 2018-05-16 Bioverativ Therapeutics Inc. Optimized factor ix gene
CA2954738A1 (en) 2014-07-29 2016-02-04 Neurimmune Holding Ag Human-derived anti-huntingtin (htt) antibodies and uses thereof
MY180054A (en) 2014-09-30 2020-11-20 Neurimmune Holding Ag Human-derived anti-dipeptide repeats (dprs) antibody
MA40835A (en) 2014-10-23 2017-08-29 Biogen Ma Inc ANTI-GPIIB / IIIA ANTIBODIES AND THEIR USES
MA40861A (en) 2014-10-31 2017-09-05 Biogen Ma Inc ANTI-GLYCOPROTEIN IIB / IIIA ANTIBODIES
JP2018504400A (en) 2015-01-08 2018-02-15 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． LINGO-1 antagonist and use for treatment of demyelinating disorders
CN106191040B (en) * 2015-04-30 2021-09-14 杭州菁因康生物科技有限公司 Gene targeting method
EA201890423A1 (en) 2015-08-03 2018-07-31 Биовератив Терапьютикс Инк. SLIGHT PROTEINS OF THE FACTOR IX, METHODS OF THEIR RECEPTION AND APPLICATION
MX2018009375A (en) 2016-02-01 2018-09-05 Bioverativ Therapeutics Inc Optimized factor viii genes.
EP3469069A4 (en) 2016-06-10 2020-01-22 Kota Biotherapeutics, LLC Compositions and methods including b lymphocyte cell line expressing membrane immunoglobulin different from secreted immunoglobulin and cytolytic function
JP2018035137A (en) 2016-07-13 2018-03-08 マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ Novel anti-fibroblast activated protein (FAP) binding agent and use thereof
AU2017297404A1 (en) 2016-07-13 2019-01-24 Biogen Ma Inc. Dosage regimens of LINGO-1 antagonists and uses for treatment of demyelinating disorders
CA3045660A1 (en) 2016-12-02 2018-06-07 Bioverativ Therapeutics Inc. Methods of treating hemophilic arthropathy using chimeric clotting factors
EP3548063A1 (en) 2016-12-02 2019-10-09 Bioverativ Therapeutics Inc. Methods of inducing immune tolerance to clotting factors
EA201991768A1 (en) 2017-01-31 2020-01-22 Байоверетив Терапьютикс Инк. FUSIONED PROTEINS BASED ON FACTOR IX AND METHODS OF PRODUCING THEM AND WAYS OF APPLICATION
SG11202009017WA (en) 2018-03-28 2020-10-29 Bristol Myers Squibb Co Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use
WO2019222682A1 (en) 2018-05-18 2019-11-21 Bioverativ Therapeutics Inc. Methods of treating hemophilia a
KR20210027352A (en) 2018-06-04 2021-03-10 바이오젠 엠에이 인코포레이티드 Anti-VLA-4 antibody with reduced effector function
CN110607326B (en) * 2018-06-15 2022-11-29 江苏省农业科学院 Non-strong start type exogenous gene expression method and application thereof in expression of target protein with toxicity
EP3844288A1 (en) * 2018-10-01 2021-07-07 Lonza Ltd. Ssi cells with predictable and stable transgene expression and methods of formation
US11028176B2 (en) 2019-02-13 2021-06-08 The Brigham And Women's Hospital, Inc. Anti-peripheral lymph node addressin antibodies and uses thereof
AU2022332276A1 (en) 2021-08-23 2024-04-04 Bioverativ Therapeutics Inc. Optimized factor viii genes
IL310963A (en) 2021-08-23 2024-04-01 Bioverativ Therapeutics Inc Closed-end dna production with inverted terminal repeat sequences
CA3232988A1 (en) 2021-09-30 2023-04-06 Bioverativ Therapeutics Inc. Nucleic acids encoding factor viii polypeptides with reduced immunogenicity

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202238A (en) * 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
FR2646438B1 (en) 1989-03-20 2007-11-02 Pasteur Institut A METHOD FOR SPECIFIC REPLACEMENT OF A COPY OF A GENE PRESENT IN THE RECEIVER GENOME BY INTEGRATION OF A GENE DIFFERENT FROM THAT OR INTEGRATION
US5464764A (en) * 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
DE69027526T3 (en) 1989-11-06 2005-03-24 Cell Genesys, Inc., Foster City PREPARATION OF PROTEINS BY HOMOLOGOUS RECOMBINATION
NZ245015A (en) 1991-11-05 1995-12-21 Transkaryotic Therapies Inc Delivery of human growth hormone through the administration of transfected cell lines encoding human growth hormone, which are physically protected from host immune response; the transfected cells and their production
AU4401993A (en) * 1992-06-04 1993-12-30 Exemplar Corporation Insertion of heterologous dna outside of known chromosomal genes
MX9305183A (en) * 1992-08-27 1994-05-31 Us Agriculture PORTABLE INTRON, VIRAL GENOMIC DNA MOLECULA, LIVE VIRUS AND CONTAINING VACCINE AND METHOD FOR OBTAINING IT.
US5648267A (en) * 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
ID24565A (en) 1997-03-14 2000-07-27 Idec Pharma Corp METHODS FOR GEN INTEGRATION IN SPECIFIC PLACES IN MAMALIA CELLS THROUGH HOMOLOGIC AND VECTOR RECOMBINATIONS FOR THE SAME ACHIEVEMENT
US5830698A (en) * 1997-03-14 1998-11-03 Idec Pharmaceuticals Corporation Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same

Also Published As

Publication number Publication date
DE69830312T2 (en) 2006-02-02
ID24565A (en) 2000-07-27
US6413777B1 (en) 2002-07-02
PL191251B1 (en) 2006-04-28
NO994397D0 (en) 1999-09-10
AU6443598A (en) 1998-10-12
CZ293355B6 (en) 2004-04-14
ES2242997T3 (en) 2005-11-16
JP4128227B2 (en) 2008-07-30
CA2283740C (en) 2006-06-27
IL131746A0 (en) 2001-03-19
RO120148B1 (en) 2005-09-30
BR9808584A (en) 2000-05-23
JP2001516221A (en) 2001-09-25
AU737155B2 (en) 2001-08-09
US7235360B2 (en) 2007-06-26
EP0981637A1 (en) 2000-03-01
US20040166528A1 (en) 2004-08-26
PT981637E (en) 2005-09-30
EP0981637B1 (en) 2005-05-25
US20020192820A1 (en) 2002-12-19
RU2004107694A (en) 2005-08-27
CN1255166A (en) 2000-05-31
DE69830312D1 (en) 2005-06-30
IN189732B (en) 2003-04-19
CZ316299A3 (en) 2000-02-16
WO1998041645A1 (en) 1998-09-24
US6841383B2 (en) 2005-01-11
ATE296356T1 (en) 2005-06-15
TWI232239B (en) 2005-05-11
CN1175111C (en) 2004-11-10
CA2283740A1 (en) 1998-09-24
NO994397L (en) 1999-11-09

Similar Documents

Publication Publication Date Title
PL335695A1 (en) Method of integrating genes into a specific place of mammal cell genome by honologous recombination and vectors serving that purpose
MY137837A (en) Novel method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same
DK1097211T3 (en) Expression of eukaryotic peptides in plant plastids
CA2203569A1 (en) Nucleotide sequence encoding the enzyme i-scei and the uses thereof
MX9605542A (en) Dna construct for effecting homologous recombination and uses thereof.
SG48099A1 (en) Adeno-associated viral (aav) liposomes and methods related thereto
DE69831417D1 (en) DUAL SELECTION CASSETTE AND PLASMIDE CONTAINING IT
ATE526818T1 (en) GENETICALLY PRODUCED DUSTWASH
EP1200557A4 (en) Method of making plant artificial chromosomes
IL133458A0 (en) Plasmids for plant transformation and method for using the same
ATE244311T1 (en) EXPRESSION SYSTEM OF ANTIBODIES DURING HOMOLOGICAL RECOMBINATION IN MUrine CELLS
WO1999021976A3 (en) Rapid generation of stable mammalian cell lines producing high levels of recombinant proteins
AU5659898A (en) Gene-trapping construct for the identification and isolation of genes
WO2001079512A3 (en) Vector and method for targeted replacement and disruption of an integrated dna sequence
EP0068375A3 (en) Recombinant dna techniques for the production of relaxin
EP2281892A3 (en) Methods for producing polypeptides in respiratory-deficient Trichoderma cells
WO2001038504A3 (en) Homologous recombination in plants
WO2000052164A3 (en) Potassium channel molecules and uses therefor
ATE72837T1 (en) MULTIPLE AMPLIFIABLE VECTORS FOR HIGH EXPRESSION EXOGENIC DNA.
EP0763205A4 (en) Nucleic acid sequences controlling lung cell-specific gene expression
WO1994016074A3 (en) High molecular weight b-cell growth factor: interleukin-14
ATE259421T1 (en) DNA VIRUS VECTORS AND METHOD FOR THEIR PRODUCTION
WO2001032872A3 (en) Twik potassium channel molecules and uses therefor
HUP0002320A2 (en) Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same
WO2000037682A8 (en) Method for augmenting expression of a foreign gene

Legal Events

Date Code Title Description
RECP Rectifications of patent specification
LAPS Decisions on the lapse of the protection rights

Effective date: 20090309